The global rheumatoid arthritis therapeutics market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising prevalence of arthritis, improved treatment methods, favorable government initiatives, and rising awareness among the population.
Rheumatoid arthritis (RA) is basically an immune system malfunctioning, a blistering condition that causes ongoing torment, expanding, and disaster in the functioning capacity of joints. It significantly occurs when a person’s immune system attacks his own cells of synovium. The synovium is inside coating of layers which fundamentally covers or protects the joints. The destruction of synovium causes pain in the joints and difficulty in movement. The symptoms of RA includes stiffness in joints, aching or pain in more than one joint, swelling and tenderness in joints, fever, fatigue or tiredness, weight loss, and weakness. RA can impact other tissues of the body and cause disorders in organs such as the heart, lungs, and eyes. The risk factors for RA are obesity, smoking, genetic inheritance, and old age.
According to the Centre for Disease Control and Prevention (CDC), in 2013–2015, around 54 million US adults, which was 22.7% of total population per year suffered from some kind of arthritis, lupus, rheumatoid arthritis, gout, or fibromyalgia. The same report estimated that till 2040, an around 78 million, representing 26% of US adults of age 18 years or more are projected to get diagnosed with arthritis. This high prevalence rate is likely boost the market in the near future.
The COVID-19 pandemic has brought huge impact on global market with restrictions and nationwide lockdowns worldwide. The RA market also witnessed negative impact due to the high burden of the coronavirus cases on the healthcare sector and reduced focus on other disease treatment as well as management. This market gained some momentum back with relaxing restriction and improving healthcare sector after the pandemic as government began to bolster their healthcare for the future events.
Key Players Covered in the Report
AbbVie; Boehringer Ingelheim GmbH; Novartis International AG; Regeneron Pharmaceuticals, Inc.; Pfizer Inc.; Bristol-Myers Squibb.; Hoffmann-La Roche AG; UCB S.A.; Johnson & Johnson.; and Amgen Inc.
Market Segment Insights
Based on molecules, the global rheumatoid arthritis therapeutics market is bifurcated into pharmaceutical and biopharmaceutical. The pharmaceutical segment is further divided into NSAIDS, analgesics, DMARDs, and glucocorticoids. The biopharmaceutical segment is sub-classified into biologics and biosimilars. The biologics segment is further segmented into TNF-α antagonists, T-cell inhibitors, CD20 antigen, JAK inhibitors, and anti-IL6 biologics. Additionally, the biosimilars segment is bifurcated into CD20 antigen and TNF-α antagonists. The biopharmaceutical segment is expected to grow at a rapid pace during the forecast period attributing to the high efficiency of the treatment. The biologics are more in demand than the biosimilars as the doctors prefer biologics.
Biologic drugs are anticipated to hold a major revenue share in developed markets in the coming future. However, in developing economies such as Mexico, Brazil, and South Africa, these drugs face several challenges from pharmaceutical generics and biosimilars due to expensive biologics in the market. The biosimilars segment is expected to exhibit a considerable growth rate in the near future as these drugs are cheap, easily available, and demonstrate high efficiency in terms of results. Due to launch of new products in the segment, biosimilars are gaining popularity in the developed nations as well and the developing nations are preferring biosimilars due to its cheap price. The pharmaceutical segment is the first-line of treatment for RA. So, this segment is also growing at a good pace. With new developments and technological advancement in the segment the market is set to grow at considerable rate.
On the basis of sales channel, the market is bifurcated into prescription and over-the-counter (OTC). The prescription segment is projected to expand at a considerable CAGR owing to the growing awareness among the people regarding the need of prescribed by the doctor to avoid worsening of the disease or side-effect of the drugs. As prolonged use of RA drugs sometimes results in drug resistance, due to which patients suffering from this disease are expected to consult rheumatologists and follow prescribed drugs. Moreover, there are inadequate number of OTC products available, which makes the prescribed drugs to dominate in the coming future.
In terms of regions, the global rheumatoid arthritis therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of the North America is anticipated to constitute a major market share in the coming years. Improved awareness of disease therapies among patients, rising prevalence of RA, and high public and non-government organization on healthcare expenditure are pushing the growth of the regional market. Additionally, favorable reimbursement policies, easy access to quality healthcare, strong clinical pipeline, and approval of novel drugs are anticipated to encourage the overall revenue share of North America.
Get Sample Report @ Request For Sample of Rheumatoid Arthritis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast | Growth Market Reports
About Growth Market Reports:
Growth Market Reports provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. Growth Market Reports has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: sales@growthmarketreports.com
Web: https://growthmarketreports.com
Follow Us: LinkedIn | Twitter
0
